Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SIRPγ limits effector differentiation of human CD8 T cells in response to subthreshold TCR-signaling.

ImmunoHorizons·2026
Same author

Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.

International journal of molecular sciences·2025
Same author

SIRPγ modulates effector differentiation of human CD8 T Cells under suboptimal TCR stimulation: implications for immune homeostasis and autoimmunity.

bioRxiv : the preprint server for biology·2025
Same author

MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.

Frontiers in immunology·2025
Same author

Correction: K27-linked RORγt ubiquitination by Nedd4 potentiates Th17-mediated autoimmunity.

Journal of biomedical science·2025
Same author

K27-linked RORγt ubiquitination by Nedd4 potentiates Th17-mediated autoimmunity.

Journal of biomedical science·2025
Same journal

Spinal cord microglia exhibit a dysfunctional response to myelin damage.

Journal of neuroimmunology·2026
Same journal

Methodological concerns in the cutoff determination of a flow cytometric MOG-IgG assay: The need for independent validation.

Journal of neuroimmunology·2026
Same journal

Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

Journal of neuroimmunology·2026
Same journal

Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.

Journal of neuroimmunology·2026
Same journal

Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.

Journal of neuroimmunology·2026
Same journal

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

RTL therapy for multiple sclerosis: a Phase I clinical study.

Halina Offner1, Sushmita Sinha, Gregory G Burrows

  • 1Neuroimmunology Research, Veterans Affairs Medical Center, 3710 SW US Veterans' Hospital Rd., Portland, OR 97239, United States. offnerva@ohsu.edu

Journal of Neuroimmunology
|October 23, 2010
PubMed
Summary
This summary is machine-generated.

RTL1000, a novel therapy for multiple sclerosis (MS), demonstrated safety and tolerability in a Phase 1 study. This T cell receptor ligand shows promise for treating MS without causing global immunosuppression.

More Related Videos

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Related Experiment Videos

Last Updated: Jun 7, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS).
  • Current MS treatments often involve broad immunosuppression, leading to potential side effects.
  • There is a need for targeted therapies that modulate the immune response without compromising overall immunity.

Purpose of the Study:

  • To evaluate the safety and tolerability of RTL1000 in subjects with multiple sclerosis.
  • To assess the potential of RTL1000 as a novel therapeutic agent for MS.

Main Methods:

  • A Phase 1, randomized, placebo-controlled, escalating dose study.
  • 34 subjects with multiple sclerosis participated in the study.
  • Administration of human recombinant T cell receptor ligand (RTL1000).

Main Results:

  • RTL1000 was found to be safe and well tolerated at doses up to 60 mg.
  • No worsening of MS disease was observed at doses up to 200 mg.
  • The effective dose range for EAE was well within the tested limits.

Conclusions:

  • RTL1000 represents a novel therapeutic approach for multiple sclerosis.
  • The treatment shows potential for potent immunoregulation and CNS repair.
  • RTL1000 offers a promising alternative to global immunosuppression in MS treatment.